A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.

Clinical Trial Description

Approximately 750-900 people in the United States each year develop synovial sarcoma, a rare form of cancer of connective tissue. This tumor frequently metastasizes to other parts of the body such as the lungs. Chemotherapy can sometimes decrease the size of the recurrent tumors, but these results are usually only temporary, and the tumors grow again. We are trying to exploit some of the proteins made by synovial sarcoma (cancer-germ cell or cancer-testis antigens) as targets for the immune system. Specifically, we are investigating if immune-based therapy with anti-CTLA-4 antibody once every 3 weeks for three treatments will activate the immune system enough to attack recurrent synovial sarcoma. In this study the tumor itself serves as the "vaccine" or source of protein, as we try to activate tumor-fighting T cells with the anti-CTLA-4. Anti-CTLA-4 takes the brakes off the immune system to allow otherwise hidden immune responses to become more active. In so doing, there could be other side effects, such as immune system attacks against the normal organs of the body. We will follow both the anti-tumor immune responses with frequent blood tests and follow and treat side effects people develop on this study to determine if anti-CTLA-4 is worth pursuing in a larger number of patients with synovial sarcoma or other sarcomas. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00140855
Study type	Interventional
Source	Ludwig Institute for Cancer Research
Contact
Status	Terminated
Phase	Phase 2
Start date	June 8, 2005
Completion date	July 1, 2007

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03399448` - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)	Phase 1
Terminated	`NCT01957709` - Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma	Early Phase 1
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Active, not recruiting	`NCT02869217` - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors	Phase 1
Completed	`NCT01674101` - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy	N/A
Completed	`NCT03250325` - Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma	Phase 1/Phase 2
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Terminated	`NCT03520959` - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)	Phase 3
Terminated	`NCT02683148` - DHEA in Synovial Sarcoma Patients	Phase 1
Recruiting	`NCT05642455` - SPEARHEAD-3 Pediatric Study	Phase 1/Phase 2
Active, not recruiting	`NCT04420975` - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma	Phase 1
Recruiting	`NCT02983539` - Detection of Circulating Tumor Cells in Patients With Sarcomas
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Active, not recruiting	`NCT03132922` - MAGE-A4ᶜ¹º³²T for Multi-Tumor	Phase 1
Terminated	`NCT04145700` - CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Phase 1/Phase 2
Completed	`NCT00004853` - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy	Phase 1
Suspended	`NCT06083883` - Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1	Phase 1
Terminated	`NCT05355753` - A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors	Phase 1/Phase 2
Withdrawn	`NCT05116800` - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma	Phase 2
Recruiting	`NCT03638206` - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	Phase 1/Phase 2